TY - JOUR
T1 - Transcatheter Aortic Valve Replacement in Patients with Coronary Chronic Total Occlusion
AU - Gifft, Kristina
AU - Brilakis, Emmanouil
AU - Kumar, Arun
AU - Omran, Jad
AU - Enezate, Tariq
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6
Y1 - 2020/6
N2 - Introduction: Coronary artery disease is a common diagnosis among patients evaluated for transcatheter aortic valve replacement (TAVR). It is unknown whether the presence of coronary artery chronic total occlusion (CTO) has any impact on TAVR post-procedural in-hospital outcomes. Methods: The study population was extracted from the 2016 Nationwide Readmissions Data using International Classification of Diseases, tenth edition, clinical modifications/procedure coding system codes for TAVR, coronary CTO and post-procedural complications. Study endpoints included in-hospital all-cause mortality, length of index hospital stay, paravalvular leak (PVL), mechanical complications of prosthetic valve, cardiogenic shock, acute myocardial infarction (AMI), acute kidney injury (AKI), need for a permanent pacemaker, and bleeding. Propensity matching was used to extract a matched control (TAVR-M group to TAVR-CTO group). Results: There were 23,604 TAVR, of whom, 467 discharges were identified in each group. Baseline characteristics and comorbidities were comparable. Mean age was 80.5 years and 45.9% were female. In comparison to TAVR-M, TAVR-CTO was associated with longer length of stay (8.1 versus 5.9 days, p < 0.01), and higher incidence of post-procedural cardiogenic shock (5.1% versus 1.7%, p < 0.01), AMI (5.8% versus 2.8%, p = 0.02), and AKI (18.6% versus 13.9, p = 0.048). There was no significant difference between the two groups in in-hospital all-cause mortality (1.7% versus 2.4%, p = 0.49), PVL (1.3% versus 0.4%, p = 0.16), mechanical complications of prosthetic valve (0.4% versus 0.9%, p = 0.41), permanent pacemaker (11.6% versus 8.1%, p = 0.07), or bleeding (20.6% versus 19.7%, p = 0.74). Conclusions: In comparison to TAVR-M, TAVR-CTO was associated with a higher incidence of cardiogenic shock, AMI, and AKI and longer LOS but similar mortality.
AB - Introduction: Coronary artery disease is a common diagnosis among patients evaluated for transcatheter aortic valve replacement (TAVR). It is unknown whether the presence of coronary artery chronic total occlusion (CTO) has any impact on TAVR post-procedural in-hospital outcomes. Methods: The study population was extracted from the 2016 Nationwide Readmissions Data using International Classification of Diseases, tenth edition, clinical modifications/procedure coding system codes for TAVR, coronary CTO and post-procedural complications. Study endpoints included in-hospital all-cause mortality, length of index hospital stay, paravalvular leak (PVL), mechanical complications of prosthetic valve, cardiogenic shock, acute myocardial infarction (AMI), acute kidney injury (AKI), need for a permanent pacemaker, and bleeding. Propensity matching was used to extract a matched control (TAVR-M group to TAVR-CTO group). Results: There were 23,604 TAVR, of whom, 467 discharges were identified in each group. Baseline characteristics and comorbidities were comparable. Mean age was 80.5 years and 45.9% were female. In comparison to TAVR-M, TAVR-CTO was associated with longer length of stay (8.1 versus 5.9 days, p < 0.01), and higher incidence of post-procedural cardiogenic shock (5.1% versus 1.7%, p < 0.01), AMI (5.8% versus 2.8%, p = 0.02), and AKI (18.6% versus 13.9, p = 0.048). There was no significant difference between the two groups in in-hospital all-cause mortality (1.7% versus 2.4%, p = 0.49), PVL (1.3% versus 0.4%, p = 0.16), mechanical complications of prosthetic valve (0.4% versus 0.9%, p = 0.41), permanent pacemaker (11.6% versus 8.1%, p = 0.07), or bleeding (20.6% versus 19.7%, p = 0.74). Conclusions: In comparison to TAVR-M, TAVR-CTO was associated with a higher incidence of cardiogenic shock, AMI, and AKI and longer LOS but similar mortality.
KW - Coronary chronic total occlusion
KW - Outcomes
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85075339952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075339952&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2019.10.025
DO - 10.1016/j.carrev.2019.10.025
M3 - Article
C2 - 31706735
AN - SCOPUS:85075339952
SN - 1553-8389
VL - 21
SP - 741
EP - 744
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
IS - 6
ER -